Orthofix Announces FDA Clearance and First Patient Implants of FIREBIRD SI Fusion System for Low Back Pain

June 29, 2020

Orthofix Medical today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance and the first patient implants of the FIREBIRD SI Fusion System. Designed to compress and stabilize the sacroiliac joint (also called the SI joint) during fusion, the FIREBIRD SI Fusion System is the first 3D printed titanium bone screw to launch in the U.S. for treating SI joint dysfunction.

“Pain in the lower back and buttocks may often be caused by degeneration of the SI joint as a result of stress to the joint during pregnancy or childbirth, everyday normal wear and tear, or an injury such as a fall,” said Dr. Justin Hall, an orthopedic surgeon who implanted the first patients at Baptist Memorial Hospital-Golden Triangle in Columbus, MS. “Sacroiliac joint fusion is an important treatment option to reduce pain through a minimally invasive procedure that can enable patients to return to better function and quality of life.”

The FIREBIRD SI Fusion System is designed with a porous mid-shaft region that allows bone to grow into its surface – creating a bond between the implant and the patient’s bone at the SI joint. Featuring a cannulated screw design, the system enables the surgeon to pack the device with autograft and/or allografts like the Trinity ELITE Allograft with viable cells to help ensure bone fusion. The FIREBIRD SI screws are available in an assortment of lengths and diameters to address a variety of patient anatomies. This novel system is being launched in the U.S through a limited market release.

“Orthofix Spine prides itself in creating differentiated technology for the advancement of patient care,” said Kevin Kenny, Global President of Orthofix Spine. “We are excited to bring the FIREBIRD SI Fusion System to market as an extension of our flagship FIREBIRD line of devices. This new system is another example of our commitment to providing surgeons and their patients with innovative options that interface with products and solutions within our portfolio.”

The FIREBIRD SI Fusion System is implanted through a minimally invasive surgery that typically can be performed in about an hour and may lead to less time at the hospital and a faster recovery than a traditional sacroiliac joint fusion surgery. The procedure with the FIREBIRD SI Fusion System involves inserting two to four bone screws across the SI Joint to stabilize during the fusion process.

 

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

OTHER NEWS

"Receiving this first FDA clearance for our retinal camera is not just a milestone, it's a leap forward in our quest to safeguard the vision of millions," said Dr. Patrick Sauvageau, optometrist, CEO, and co-founder of Zilia. "We're now focused on obtaining De Novo classification for ocular oximetry, a breakthrough biomarker that promises to revolutionize how we diagnose and manage a variety of ocular conditions."
The recent FDA clearances included Brainomix 360 e-CTP and Brainomix 360 e-MRI, both software modules that can support thrombolysis and thrombectomy treatment decisions, particularly for late-window patients who present to hospital more than 6-12 hours after stroke onset.
IONIC Health’s 510(k)-pending nCommand Lite technology is designed to include vendor-agnostic remote scanning capabilities. This strategic collaboration’s goal is to enable GE HealthCare to provide a multi-vendor, multi-modality remote scanning solution to healthcare systems and patients around the globe.
Silmitasertib works by inhibiting CK2 protein kinase, which have implicated in regulation of several signaling pathways that are important for innate immune responses. CK2 modulates inflammatory pathways, including NF-κB, PI3K–Akt–mTOR, and JAK–STAT.
"This is the culmination of years of research and development to deliver a medical device that helps improve the lives of patients suffering from spinal stenosis. Our recent move to larger premises in the Research Park at FAU will allow us to train our surgical and distribution partners to become increasingly competitive in the spinal implant device market,” said Peter Harris, founder and CEO of FloSpine.

By using this website you agree to accept Medical Device News Magazine Privacy Policy